Identification of Novel Biomarker and Therapeutic Target Candidates for Diagnosis and Treatment of Follicular Adenoma

Cancer Genomics - Proteomics

XIANYIN LAI²  SHAOXIONG CHEN¹ 

[1] epartment of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, U.S.A.epartment of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, U.S.A.epartment of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, U.S.A.;epartment of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, U.S.A.epartment of Cellular & Integrative Physiology, Indiana University School of Medicine, Indianapolis, IN, U.S.A.epartment of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, U.S.A.epartment of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, U.S.A.epartment of Cellular & Integrative Physiology, Indiana University School of Medicine, Indianapolis, IN, U.S.A.epartment of Cellular & Integrative Physiology, Indiana University School of Medicine, Indianapolis, IN, U.S.A.epartment of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, U.S.A.epartment of Cellular & Integrative Physiology, Indiana University School of Medicine, Indianapolis, IN, U.S.A.

关键词: Adenoma;    biomarker;    follicular;    mass spectrometry;    therapeutic target;   

DOI  :  

来源: Delinasios GJ CO

【 摘 要 】

Follicular adenoma is a type of benign and encapsulated nodule in the thyroid gland, but some adenomas have the potential to progress to follicular carcinoma. Therefore, it is important to monitor the state and progress of follicular adenoma in the clinic and discover drug development targets for the treatment of follicular adenoma to prevent its worsening to follicular carcinoma. Currently, the study of biomarkers and therapeutic targets lacks applications of up-to-date technologies, including proteomics and bioinformatics. To discover novel protein biomarker and therapeutic target candidates, a liquid chromatography-tandem mass spectrometry approach was applied to directly compare follicular adenoma with normal thyroid tissue samples. The proteomics analysis revealed 114 protein biomarker candidates out of 1,780 identified and quantified proteins. A comprehensive approach to prioritize the biomarker candidates by category and rank revealed CD63, DDB1, TYMP, VDAC2, and DCXR as the top five biomarker candidates. Upstream regulator analysis using the Ingenuity Pathway Analysis (IPA) software discovered four therapeutic target candidates for follicular adenoma, including TGFB1, MYC, ANGPT2, and NFE2L2. This study provided biomarker and therapeutic target candidates for a follow-up study, which will facilitate monitoring and treatment of follicular adenoma.

【 授权许可】

Unknown